Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2018 Filed Nov 3, 2018 01:17 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
OtherCommon Stock | 494 | $23.60 | $11,656.42 |
DisclosureSEC source: 0001209191-18-057056 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2018. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 01:12 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053532 · doc4.xml · derivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,416 Underlying: Common Stock · 6,000 shares Expires 2026-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016). Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 01:12 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
SaleCommon Stock | 6,000 | $32.07 | $192,433.20 |
DisclosureSEC source: 0001209191-18-053532 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F2 · price: The range of sales prices received was $31.75 to $32.38. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 01:12 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionCommon Stock | 6,000 | $13.00 | $78,000.00 |
DisclosureSEC source: 0001209191-18-053532 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. Read SEC document |
| September 14, 2018 Filed Sep 14, 2018 15:41 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 19,675 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001209191-18-050997 · doc4.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,601 Underlying: Common Stock · 19,675 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cash exercise and hold. F2 · derivative.exercise_date: At the date of filing, 523,101 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| September 14, 2018 Filed Sep 14, 2018 15:41 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 19,675 | $7.20 | $141,660.00 |
DisclosureSEC source: 0001209191-18-050997 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cash exercise and hold. Read SEC document |
| September 12, 2018 Filed Sep 12, 2018 16:28 UTC |
TANG KEVINDirector · 10% owner
TANG CAPITAL MANAGEMENT LLC10% owner
TANG CAPITAL PARTNERS LP10% owner
|
SaleCommon Stock | 2,695,000 | $35.75 | $96,346,250.00 |
DisclosureSEC source: 0001209191-18-050601 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 5,830,215 F1 · kind: The Reporting Person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 192,308 shares of common stock purchased by the Reporting Person on March 29, 2018. The Reporting Person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein. F2 · ownership.direct: The securities are held by Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. F2 · ownership.nature: The securities are held by Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:05 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-18-041386 · doc4.xml · derivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,416 Underlying: Common Stock · 6,000 shares Expires 2026-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016). Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:05 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
SaleCommon Stock | 100 | $38.85 | $3,885.00 |
DisclosureSEC source: 0001209191-18-041386 · doc4.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:05 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
SaleCommon Stock | 5,900 | $37.51 | $221,293.66 |
DisclosureSEC source: 0001209191-18-041386 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F2 · price: The range of sales prices received was $37.70 to $38.60. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:05 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionCommon Stock | 6,000 | $13.00 | $78,000.00 |
DisclosureSEC source: 0001209191-18-041386 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC |
Hoffman Robert E.CFO & SVP, Finance
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $15.30 | $0.00 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · derivative · entry 5 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 30,000 shares Expires 2027-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. F5 · derivative.exercise_date: Options vest and become exercisable with respect to 32,500 shares on the first anniversary of his first day of employment (the "Grant Date"), followed by 97,500 shares vesting ratably each month over the subsequent three years, such that 130,000 options will be fully vested on the four year anniversary of the Grant Date. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC |
Hoffman Robert E.CFO & SVP, Finance
|
SaleCommon Stock | 1,060 | $38.80 | $41,123.02 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 4 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. F4 · price: The range of sales prices received was $38.625 to $38.85. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC |
Hoffman Robert E.CFO & SVP, Finance
|
SaleCommon Stock | 28,940 | $38.15 | $1,104,107.30 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 3 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,340 F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. F3 · price: The range of sales prices received was $37.60 to $38.60. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC |
Hoffman Robert E.CFO & SVP, Finance
|
Exercise / conversionCommon Stock | 30,000 | $15.30 | $459,000.00 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 95,531 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · derivative · entry 9 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 95,531 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F7 · derivative.exercise_date: At the date of filing, 412,500 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
SaleCommon Stock | 3,400 | $38.75 | $131,764.96 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · nonDerivative · entry 7 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,640 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F6 · price: The range of sales prices received was $38.55 to $38.85. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
SaleCommon Stock | 92,131 | $38.13 | $3,512,918.18 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · nonDerivative · entry 6 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,040 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F5 · price: The range of sales prices received was $37.50 to $38.50. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
Exercise / conversionCommon Stock | 95,531 | $7.20 | $687,823.20 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · nonDerivative · entry 5 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. Read SEC document |
| June 29, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 129,469 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · derivative · entry 8 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,531 Underlying: Common Stock · 129,469 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F7 · derivative.exercise_date: At the date of filing, 412,500 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| June 29, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
SaleCommon Stock | 2,112 | $41.39 | $87,415.47 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · nonDerivative · entry 4 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,640 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F4 · price: The range of sales prices received was $41.075 to $41.45. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 29, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
SaleCommon Stock | 51,696 | $40.17 | $2,076,597.30 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · nonDerivative · entry 3 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,752 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F3 · price: The range of sales prices received was $39.775 to $40.70. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 29, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
SaleCommon Stock | 75,661 | $39.14 | $2,961,121.86 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · nonDerivative · entry 2 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,448 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. F2 · price: The range of sales prices received was $38.75 to $39.75. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 29, 2018 Filed Jul 4, 2018 01:01 UTC |
Rosen RobertDirector · President
|
Exercise / conversionCommon Stock | 129,469 | $7.20 | $932,176.80 |
DisclosureSEC source: 0001209191-18-041384 · doc4.xml · nonDerivative · entry 1 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018. Read SEC document |
| June 21, 2018 Filed Jun 23, 2018 01:35 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/12/2014). Read SEC document |
| June 21, 2018 Filed Jun 23, 2018 01:35 UTC |
Quart Barry DDirector · Chief Executive Officer
|
SaleCommon Stock | 50,000 | $39.05 | $1,952,500.00 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,600 F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| June 21, 2018 Filed Jun 23, 2018 01:35 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 50,000 | $9.05 | $452,500.00 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| April 30, 2018 Filed Jun 23, 2018 01:35 UTC |
Quart Barry DDirector · Chief Executive Officer
|
OtherCommon Stock | 1,607 | $13.22 | $21,240.52 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,600 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
| April 30, 2018 Filed Jul 4, 2018 01:03 UTC |
Hoffman Robert E.CFO & SVP, Finance
|
OtherCommon Stock | 744 | $13.22 | $9,833.82 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:01 UTC |
TANG KEVINDirector · 10% owner
TANG CAPITAL MANAGEMENT LLC10% owner
TANG CAPITAL PARTNERS LP10% owner
|
PurchaseCommon Stock | 192,308 | $26.00 | $5,000,008.00 |
DisclosureSEC source: 0001209191-18-022351 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 8,525,215 F1 · ownership.direct: The securities are held by Tang Capital Partners, LP and Tang (APPA) Holdings, LLC. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. Tang Capital Partners, LP is the sole manager of Tang (APPA) Holdings, LLC. F1 · ownership.nature: The securities are held by Tang Capital Partners, LP and Tang (APPA) Holdings, LLC. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. Tang Capital Partners, LP is the sole manager of Tang (APPA) Holdings, LLC. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:24 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020737 · doc4.xml · derivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,416 Underlying: Common Stock · 18,000 shares Expires 2026-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016). Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:24 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
SaleCommon Stock | 18,000 | $30.00 | $540,000.00 |
DisclosureSEC source: 0001209191-18-020737 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:24 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionCommon Stock | 18,000 | $13.00 | $234,000.00 |
DisclosureSEC source: 0001209191-18-020737 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:22 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001209191-18-020736 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,276 Underlying: Common Stock · 100,000 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. F2 · derivative.exercise_date: At the date of filing, 542,776 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:22 UTC |
Quart Barry DDirector · Chief Executive Officer
|
SaleCommon Stock | 100,000 | $29.75 | $2,975,000.00 |
DisclosureSEC source: 0001209191-18-020736 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,993 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:22 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 100,000 | $7.20 | $720,000.00 |
DisclosureSEC source: 0001209191-18-020736 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| March 14, 2018 Filed Mar 17, 2018 01:00 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionEmployee Stock Option(Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0000899243-18-007825 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,276 Underlying: Common Stock · 100,000 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. F2 · derivative.exercise_date: At the date of filing, 642,776 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| March 14, 2018 Filed Mar 17, 2018 01:00 UTC |
Quart Barry DDirector · Chief Executive Officer
|
SaleCommon Stock | 100,000 | $24.75 | $2,475,000.00 |
DisclosureSEC source: 0000899243-18-007825 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,993 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| March 14, 2018 Filed Mar 17, 2018 01:00 UTC |
Quart Barry DDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 100,000 | $7.20 | $720,000.00 |
DisclosureSEC source: 0000899243-18-007825 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:21 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,584 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003425 · doc4.xml · derivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,416 Underlying: Common Stock · 7,584 shares Expires 2026-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016). Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:21 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
SaleCommon Stock | 7,584 | $20.00 | $151,680.00 |
DisclosureSEC source: 0001209191-18-003425 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:21 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
Exercise / conversionCommon Stock | 7,584 | $13.00 | $98,592.00 |
DisclosureSEC source: 0001209191-18-003425 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:18 UTC |
Christian WaageDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066635 · doc4.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:16 UTC |
TANG KEVINDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066630 · doc4.xml · derivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:17 UTC |
Johnson Craig ADirector
|
GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066632 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:18 UTC |
POYHONEN JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066634 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:16 UTC |
Rosen RobertDirector · President
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066629 · doc4.xml · derivative · entry 1 Rosen Robert · CIK 0001555089 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:15 UTC |
Quart Barry DDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066627 · doc4.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2027-12-18 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the Date of Grant. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:14 UTC |
MANHARD KIMBERLYExecutive VP, Drug Development
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066626 · doc4.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Executive VP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:13 UTC |
Hoffman Robert E.CFO & SVP, Finance
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 56,667 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066625 · doc4.xml · derivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,667 Underlying: Common Stock · 56,667 shares Expires 2027-12-18 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.